TLDR: Absci Corporation reported a 54% decline in second-quarter 2025 revenue to $0.6 million, alongside a widened net loss of $30.6 million. Despite the financial setbacks, the clinical-stage biopharmaceutical company secured $64 million in July 2025, extending its cash runway into the first half of 2028. Key business updates include an expanded partnership with Almirall, potentially yielding $650 million in milestone payments, and significant progress in its AI-designed drug pipeline, with clinical readouts anticipated for ABS-101 and ABS-201.
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company leveraging generative artificial intelligence for drug discovery, announced its second-quarter 2025 financial and operating results on August 12, 2025, revealing a mixed financial picture alongside strategic advancements.
The company reported a significant 54% year-over-year decline in revenue for Q2 2025, totaling $0.6 million, down from $1.3 million in the same period of 2024. This figure also fell short of consensus estimates. Concurrently, Absci’s net loss widened by 23% to $30.6 million, compared to $24.8 million in Q2 2024. The net loss per share stood at $0.24, an increase from $0.22 a year prior. Research and development (R&D) expenses saw a 34% increase, reaching $20.5 million, reflecting ongoing investments in its clinical pipeline. Conversely, selling, general, and administrative (SG&A) expenses decreased to $8.5 million, indicating some operational efficiencies.
Despite the revenue challenges, Absci successfully bolstered its financial position by raising $64 million in gross proceeds through a capital raise in July 2025. This strategic infusion of capital is projected to extend the company’s operational runway into the first half of 2028, providing a more secure financial foundation for its ambitious programs.
In terms of business development, Absci expanded its existing collaboration with Almirall to include a second target for dermatological indications. This expanded partnership holds the potential for substantial non-dilutive funding, with up to $650 million in milestone payments across the two programs, contingent on achieving all specified milestones.
Absci continues to advance its integrated AI-driven drug discovery platform, which combines cutting-edge AI models with a synthetic biology data engine to accelerate the development of innovative therapeutics. The company provided updates on its internal pipeline of AI-designed therapeutics:
ABS-101: This potentially best-in-class antibody, aimed at treating inflammatory bowel disease (IBD), is currently in a Phase 1 trial, with an interim readout anticipated in the second half of 2025.
ABS-201: A groundbreaking preclinical antibody designed for hair regrowth, specifically targeting androgenetic alopecia (male and female pattern baldness), is expected to commence a Phase 1/2a trial in early 2026, with a potential interim efficacy readout later that year.
Also Read:
- q.beyond Reports Strong Q2 2025 Earnings, Driven by AI Integration and Strategic Profitability Focus
- Artificial Intelligence in 2025: A Landscape of Integration, Innovation, and Evolving Challenges
Absci’s focus remains on leveraging its generative AI capabilities to address challenging therapeutic targets and deliver groundbreaking therapeutics to patients faster, positioning itself for future growth through its technological advancements and strategic partnerships.
